Chain Drug Review - New uses for Risperdal
Monday, January 5th, 2009 WASHINGTON — The Food and Drug Administration has approved Risperdal for two psychiatric conditions in children and adolescents.
Janssen L.P., a unit of Johnson & Johnson, received regulatory clearance for the product to treat schizophrenia (ages 13 to 17) and for the short-term treatment of manic or mixed episodes of bipolar I disorder (ages 10 to 17).
…
